Kyowa Kirin Co., Ltd.

Quick facts

Marketed products

• KHK4827-Active
• KRN23 · Endocrinology / Rare Metabolic Disorders
  KRN23 is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23), restoring phosphate reabsorption and vitamin D metabolism in patients with X-linked hypophosphatemia.
• Mitozytrex · Oncology

Phase 3 pipeline

• EN3267 · Immunology
  EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.
• KHK4827 · Cardiovascular
  KHK4827 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.
• KHK7580 · Cardiovascular
  KHK7580 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key enzyme in the intrinsic coagulation pathway.
• KHK7791 · Cardiovascular
  KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk.
• KK8398 · Immunology
  KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.
• KW-2246 · Oncology
  KW-2246 is a humanized monoclonal antibody that binds to and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.
• KW-2246 (fentanyl citrate) · Pain Management
  KW-2246 is a fentanyl citrate formulation that binds to opioid receptors in the central nervous system to produce analgesia and pain relief.
• KW-6500 · Endocrinology
  KW-6500 is a long-acting growth hormone secretagogue that stimulates growth hormone release by activating ghrelin receptors.
• OPC-262 · Immunology
  OPC-262 is a selective and potent inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
• Plasma-derived antithrombin · Cardiovascular
  Plasma-derived antithrombin is a protein that inhibits the coagulation cascade by binding to and neutralizing thrombin and other coagulation factors.
• saxaglipitin · Other

Phase 2 pipeline

• KHK4083 · Diabetes
  KHK4083 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
• KHK4563
• KHK4577
• KHK4951
• KHK6188
• KHK7580 high dose
• KHK7580 low dose
• KHK7580 middle dose
• KRN321
• ME-401

Phase 1 pipeline

• KHK2375
• KHK6640
• KK2260
• KK2269
• KK2845_1
• KK2845_2
• KK2845_3
• KK2845_4
• KK2845_5
• KK2845_6
• KK3910
• KK4277
• KK8123
• KRN951
• KW-6356 High Dose
• KW-6356 Low Dose
• KW-6356 Middle Dose
• KW-6356 X Dose
• KW-6356 Y Dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kyowa Kirin Co., Ltd. portfolio CI brief
• Kyowa Kirin Co., Ltd. pipeline updates RSS